LY2510924 + Sunitinib
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Clear Cell Renal Cell Carcinoma
Conditions
Metastatic Clear Cell Renal Cell Carcinoma
Trial Timeline
Aug 1, 2011 → Feb 1, 2017
NCT ID
NCT01391130About LY2510924 + Sunitinib
LY2510924 + Sunitinib is a phase 2 stage product being developed by Eli Lilly for Metastatic Clear Cell Renal Cell Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01391130. Target conditions include Metastatic Clear Cell Renal Cell Carcinoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Clear Cell Renal Cell Carcinoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01391130 | Phase 2 | Terminated |
Competing Products
20 competing products in Metastatic Clear Cell Renal Cell Carcinoma